Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, First-in-human, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Healthy Participants

NCT06944379 is registered in ClinicalTrials.gov with Oruka Therapeutics, Inc. as lead sponsor.

NCT NCT06944379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06944379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, First-in-human, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Healthy Participants
Lead sponsor
Oruka Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 19, 2025
Completion date
August 20, 2026
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers